RemeGen Co., Ltd.

SEHK:9995 Stock Report

Market Cap: HK$11.4b

RemeGen Management

Management criteria checks 3/4

RemeGen's CEO is Jianmin Fang, appointed in Oct 2008, has a tenure of 16.25 years. total yearly compensation is CN¥14.66M, comprised of 37% salary and 63% bonuses, including company stock and options. directly owns 11.44% of the company’s shares, worth HK$1.30B. The average tenure of the management team and the board of directors is 4.7 years and 4.7 years respectively.

Key information

Jianmin Fang

Chief executive officer

CN¥14.7m

Total compensation

CEO salary percentage37.0%
CEO tenure16.3yrs
CEO ownership11.4%
Management average tenure4.7yrs
Board average tenure4.7yrs

Recent management updates

Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

Jun 21
Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

Recent updates

There's No Escaping RemeGen Co., Ltd.'s (HKG:9995) Muted Revenues Despite A 25% Share Price Rise

Nov 27
There's No Escaping RemeGen Co., Ltd.'s (HKG:9995) Muted Revenues Despite A 25% Share Price Rise

Improved Revenues Required Before RemeGen Co., Ltd. (HKG:9995) Stock's 31% Jump Looks Justified

Sep 28
Improved Revenues Required Before RemeGen Co., Ltd. (HKG:9995) Stock's 31% Jump Looks Justified

RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 20
RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet

Jul 22
Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet

Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

Jun 21
Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Apr 04
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Is RemeGen (HKG:9995) Using Debt In A Risky Way?

Mar 24
Is RemeGen (HKG:9995) Using Debt In A Risky Way?

RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Feb 18
RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

Dec 29
Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Oct 16
RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?

Aug 03
Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?

Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?

Jun 22
Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?

RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected

May 10
RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?

Mar 09
Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?

RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

May 04
RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08
RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 23
RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Jan 21
We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?

Nov 30
Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?

CEO Compensation Analysis

How has Jianmin Fang's remuneration changed compared to RemeGen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CN¥2b

Jun 30 2024n/an/a

-CN¥2b

Mar 31 2024n/an/a

-CN¥2b

Dec 31 2023CN¥15mCN¥5m

-CN¥2b

Sep 30 2023n/an/a

-CN¥1b

Jun 30 2023n/an/a

-CN¥1b

Mar 31 2023n/an/a

-CN¥1b

Dec 31 2022CN¥27mCN¥5m

-CN¥999m

Sep 30 2022n/an/a

CN¥276m

Jun 30 2022n/an/a

CN¥231m

Mar 31 2022n/an/a

CN¥174m

Dec 31 2021CN¥8mCN¥4m

CN¥276m

Compensation vs Market: Jianmin's total compensation ($USD2.00M) is above average for companies of similar size in the Hong Kong market ($USD573.10K).

Compensation vs Earnings: Jianmin's compensation has been consistent with company performance over the past year.

CEO

Jianmin Fang (61 yo)

16.3yrs

Tenure

CN¥14,658,000

Compensation

Dr. Jianmin Fang is Co-Founder at RemeGen Co. Ltd. He has been Director, Chief Executive Officer and GM of RemeGen Co. Ltd. and served as its Chief Scientific Officer since October 16, 2008 to 2023 and red...

Leadership Team

NamePositionTenureCompensationOwnership
Weidong Wang
Co-Founder & Executive Chairman11.3yrsCN¥15.15mno data
Jianmin Fang
Co-Founder16.3yrsCN¥14.66m11.44%
HK$ 1.3b
Shaojing Tong
CFO & Joint Company Secretary1.3yrsCN¥1.25mno data
Ruyi He
Chief Medical & Strategy Officerno dataCN¥24.01m0.00090%
HK$ 102.2k
Jian Lin
Executive Directorno dataCN¥1.13mno data
Kaisheng Huang
Chief Operating Officerno datano datano data
Marie Zhu
Chief Technical Officerno datano datano data
Zhulun Wang
Chief Scientific Officerno datano datano data
Xiaoming Yang
Chief Manufacturing Officerno datano datano data
Qingkai Wen
Board Secretary4.7yrsno datano data

4.7yrs

Average Tenure

61yo

Average Age

Experienced Management: 9995's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Weidong Wang
Co-Founder & Executive Chairman11.3yrsCN¥15.15mno data
Jianmin Fang
Co-Founder16.3yrsCN¥14.66m11.44%
HK$ 1.3b
Ruyi He
Chief Medical & Strategy Officer4.7yrsCN¥24.01m0.00090%
HK$ 102.2k
Jian Lin
Executive Director16.5yrsCN¥1.13mno data
Lorne Alan Babiuk
Member of Scientific Advisory Boardno dataCN¥125.00kno data
Marsha A. Moses
Member of Scientific Advisory Boardno datano datano data
Gang Pei
Member of Scientific Advisory Boardno datano datano data
Liqiang Wang
Non-Executive Director4.7yrsno datano data
Xiaodi Su
Non-Executive Director4.7yrsno datano data
Xianjing Hao
Independent Non-Executive Director4.7yrsCN¥300.00kno data
Guangke Ren
Chairman of the Supervisory Board4.7yrsno datano data
Yunjin Chen
Independent Non-Executive Director2.7yrsCN¥300.00kno data

4.7yrs

Average Tenure

59yo

Average Age

Experienced Board: 9995's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 05:31
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RemeGen Co., Ltd. is covered by 35 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.
Shun Kei LawCCB International Securities Limited